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Abstract
Objective
To systematically evaluate the efficacy of treatments for tics and the risks associated with their
use.
Methods
This project followed themethodologies outlined in the 2011 edition of the American Academy
of Neurology’s guideline development process manual. We included systematic reviews and
randomized controlled trials on the treatment of tics that included at least 20 participants (10
participants if a crossover trial), except for neurostimulation trials, for which no minimum
sample size was required. To obtain additional information on drug safety, we included cohort
studies or case series that specifically evaluated adverse drug effects in individuals with tics.
Results
There was high confidence that the Comprehensive Behavioral Intervention for Tics was more
likely than psychoeducation and supportive therapy to reduce tics. There was moderate con-
fidence that haloperidol, risperidone, aripiprazole, tiapride, clonidine, onabotulinumtoxinA
injections, 5-ling granule, Ningdong granule, and deep brain stimulation of the globus pallidus
were probably more likely than placebo to reduce tics. There was low confidence that pimozide,
ziprasidone, metoclopramide, guanfacine, topiramate, and tetrahydrocannabinol were possibly
more likely than placebo to reduce tics. Evidence of harm associated with various treatments
was also demonstrated, including weight gain, drug-induced movement disorders, elevated
prolactin levels, sedation, and effects on heart rate, blood pressure, and ECGs.
Conclusions
There is evidence to support the efficacy of various medical, behavioral, and neurostimulation
interventions for the treatment of tics. Both the efficacy and harms associated with inter-
ventions must be considered in making treatment recommendations.
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This article summarizes the findings of a systematic review,
conducted as the foundation of an American Academy of
Neurology (AAN) practice guideline on the treatment of tics
in people with Tourette syndrome (TS) and chronic
tic disorders. A companion article summarizes the assessment
and treatment recommendations and suggestions for future
research. The complete and unabridged practice guideline
(systematic review, recommendations, and suggestions for
future research) is available at links.lww.com/WNL/A883
and includes full details of the methodology used, including
the risk of bias assessment for each study, meta-analysis, and
confidence in evidence determinations; space restrictions
precluded more detailed description in this article.
TS is a neurodevelopmental condition that is characterized by
the presence of multiple motor tics and at least 1 vocal tic that
persists for at least 1 year.1 Motor tics are defined as sudden,
rapid, recurrent, and nonrhythmic movements. Vocal tics are
essentially motor tics that involve the nasal or respiratory
muscles, resulting in simple sounds such as sniffing, throat
clearing or coughing, or complex vocalizations, including
coprolalia, but they also may manifest with speech blocking or
stuttering-like symptoms. Tics are often accompanied by
specific behavioral symptoms.2,3 Persistent (chronic) motor
tic disorder is characterized by the presence of motor tics only,
which persist for more than 1 year. Persistent (chronic) vocal
tic disorder is characterized by the presence of vocal tics only,
which persist for more than 1 year. Epidemiologic studies that
used current diagnostic criteria have consistently shown that
the prevalence figures for TS in school children range from
0.4% to 1.5% across all cultures, while the prevalence of
chronic tic disorders ranges from 0.9% to 2.8%.4 There are few
population-based estimates of the prevalence of TS in adults;
one recent population-based study found a prevalence of di-
agnosed TS of approximately 1 per 1,000.5 TS and chronic tic
disorders are believed to share a common neurobiological
origin, and we use the abbreviation TS throughout the article
to refer to all individuals with primary chronic tic disorders.
The majority of patients with TS, both in specialist clinics and
in the community, report the presence of behavioral symp-
toms associated with their tics: most commonly obsessive-
compulsive disorder (or obsessive-compulsive behavior) and
attention-deficit/hyperactivity disorder (ADHD).6 Lifetime
prevalence of comorbid behavioral disorders is estimated to
approach 90%.7 Patients with TS also report higher rates of
impulse control, anxiety, and affective disorders compared
with people in the general population.7,8 It is worth noting
that the associated behavioral comorbidities often compro-
mise the overall well-being of patients with TS to a much
greater extent than tic severity.9,10
The purpose of this systematic review is to assess all random-
ized controlled trials that evaluate the efficacy of medical and
behavioral treatments for tics, including neurostimulation,
and the risks associated with their use. The systematic review
was performed to develop recommendations pertaining to
the treatments of tics in children and adults with TS or
chronic tic disorders. Antipsychotic medications have been
commonly prescribed for this purpose since the 1960s. The
adverse effects associated with antipsychotic medications,
including movement disorders such as acute and tardive
dystonia, tardive dyskinesia, akathisia, and drug-induced
parkinsonism, and metabolic adverse effects, such as weight
gain, hyperlipidemia, and hyperglycemia, have led clinicians
to search for other effective treatments. In recent years, there
has been a resurgence in the interest in behavioral treatments
and neuromodulation for tics, yielding expanding evidence
in this area.
Clinical questions
The systematic review for this practice guideline addressed
the following questions:
1. In children and adults with TS or a chronic tic disorder,
which medical, behavioral, and neurostimulation inter-
ventions, compared with placebo or other active inter-
ventions, improve tic severity?
2. In children and adults with TS or a chronic tic disorder,
what are the risks of harm, including weight gain, elevated
prolactin levels, sedation, drug-induced movement dis-
orders, hypotension, bradycardia, and ECG changes with
medical treatments, compared with placebo or other active
interventions?
Description of the analytic process
In May 2016, the Guideline Development, Dissemination,
and Implementation (GDDI) Subcommittee of the AAN
recruited a multidisciplinary panel to develop the guideline,
including 9 physicians, 2 psychologists, and 2 patient repre-
sentatives. The patient representatives are both associated
with the Tourette Association of America. All panel members
Supplemental Data
Full measurement set
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Glossary
AAN = American Academy of Neurology; ADHD = attention-deficit/hyperactivity disorder; CI = confidence interval; COI =
conflict of interest; DBS = deep brain stimulation; GDDI = Guideline Development, Dissemination, and Implementation;
rTMS = repetitive transcranial magnetic stimulation; SMD = standardizedmean difference;TS =Tourette syndrome; YGTSS =
Yale Global Tic Severity Scale.
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were required to submit online conflict of interest (COI)
forms and copies of their curriculum vitae. All authors de-
termined to have COI were not permitted to review or rate
the evidence.
This evidence-based practice guideline follows the meth-
odologies described in the 2011 edition of the AAN’s guide-
line development process manual,11 as amended to include
use of the revised scheme for classifying therapeutic arti-
cles, the GDDI Guideline Topic Nomination Process
scoring tool, and the change in order of steps for external
review.
Study screening and selection criteria:
Inclusion criteria for article selection
We included systematic reviews and randomized controlled
trials on the treatment of tics in individuals with TS or chronic
tic disorders that included at least 20 participants (10 par-
ticipants if a crossover trial), except for neurostimulation tri-
als, for which no minimum sample size was required. To
obtain additional information on drug safety, we included
cohort studies or case series that specifically evaluated adverse
drug effects in individuals with TS.
Types of participants
We included individuals with TS or chronic tic disorders of
any age or sex.
Types of intervention
We included any medical, behavioral, or neurostimulation
(e.g., transcranial magnetic stimulation, deep brain stimula-
tion [DBS]) intervention for tics.
Comparison group
We included studies that compared medical, behavioral, or
neurostimulation treatments with placebo or other active
treatments.
Types of outcome measures
We assessed the effect of all treatments on measures of tic
severity and tic-related impairment. The preferred instrument
for evaluation of tic severity and tic-related impairment was
the Yale Global Tic Severity Scale (YGTSS), and when out-
come results with this instrument were reported, they were
used to calculate effect size. The YGTSS, the most extensively
deployed rating scale for tics internationally, has displayed
very good internal consistency, interrater reliability, and
convergent and divergent validity.12 Weight gain was assessed
through reported measurements in kilograms. Elevated pro-
lactin levels were evaluated by assessing mean changes in
prolactin levels between groups, or mean prolactin levels at
endpoint between groups. Drug-induced movement dis-
orders were based on assessments that used validated scales,
including the Extrapyramidal Symptoms Rating Scale, Barnes
Akathisia Scale, Simpson Angus Scale, or the Abnormal
Involuntary Movement Scale, or by clinician report. Seda-
tion was evaluated by patient/parent/clinician report and
assessment. Hypotension and bradycardia were evaluated by
assessing reported changes in systolic and diastolic blood
pressure and heart rate with treatment and reported rates of
presyncope and syncope. Reported ECG changes were also
included.
The initial search was conducted in August 2016 and included
MEDLINE, EMBASE, PsychINFO, CENTRAL, and Clin-
icalTrials.gov. The total number of references retrieved after
duplicates were removed was 2,196. After 2 reviewers, work-
ing independently of each other, reviewed the abstracts and
titles of these 2,196 references, the articles for 192 were se-
lected and obtained for full-text review. This included 16
systematic reviews, for which the references of all included
studies were examined for missing studies. Four additional
studies were identified using this method. In total, 66 ran-
domized controlled trials and 12 studies that evaluated drug
safety were included in our analysis. Two nonconflicted panel
members rated the class of evidence for each article according
to the AAN scheme for classification of therapeutic articles
(revised as denoted in a 2011 process manual amendment).
Disagreements were resolved by a third panel member.
Outcome data from included studies were extracted by the
guideline methodologist and verified by a second panel
member.
A repeat search was conducted in September 2017 to update
our search results, with a total of 211 new abstracts retrieved
after duplicate removal. Seven abstracts were selected for full-
text review, and 3 articles met our inclusion criteria and were
added to the analysis.
The effect size, or standardized mean difference (SMD), was
calculated for each study intervention/outcome pair. The
SMD expresses the size of the intervention effect relative to
the variability observed in each study. For our analysis, an
SMD of 0.20 was considered the minimal clinically mean-
ingful difference for reduction in tic severity; effect sizes
smaller than 0.10 were considered clinically unimportant.
There were a number of studies that did not provide ade-
quate data to reliably calculate effect sizes.13–20 If multiple
studies were available that evaluated the same intervention/
outcome pair, only those studies with the lowest risk of bias
were used in formulating the confidence in evidence state-
ments. A random effects meta-analysis was performed when
appropriate to synthesize results of trials that studied the
same intervention and outcome.
A modified form of the Grading of Recommendations As-
sessment, Development, and Evaluation (GRADE) process
was used to develop conclusions.21 The confidence in the
evidence (high, moderate, low, or very low) is anchored to the
error domain—class of evidence, indirectness of evidence,
and precision of effect estimate—with the highest risk of error
(see unabridged practice guideline for complete details on the
evidence synthesis process).
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Analysis of evidence
In children and adults with TS or a chronic tic
disorder, which medical, behavioral, and
neurostimulation interventions, compared
with placebo or other active interventions,
improve tic severity?
Unless otherwise specified, trial participants included both
children (individuals aged 18 years and younger) and adults
(individuals older than 18 years).
High confidence in the evidence
People with tics receiving the Comprehensive Behavioral
Intervention for Tics are more likely than those receiving
supportive psychotherapy to have reduced tic severity (SMD
0.56; 95% confidence interval [CI] 0.31–0.82, high confi-
dence, 2 Class I studies22,23).
Moderate confidence in the evidence
People with tics receiving the following interventions are
probably more likely than those receiving placebo to have
reduced tic severity:
c Haloperidol, SMD 0.59 (95% CI 0.11–1.06), 2 Class II
studies24,25
c Risperidone, SMD 0.79 (95% CI 0.31–1.27), 2 Class II
studies26,27
c Aripiprazole, SMD 0.64 (95% CI 0.31–0.97), 1 Class I
study28 and 1 Class II study29 (children only)
c Tiapride, SMD 0.62 (95% CI 0.36–0.88), 1 Class I
study30 (children only)
c Clonidine, SMD 0.45 (95% CI 0.13–0.77), 1 Class I
study31 and 2 Class II studies32,33
c OnabotulinumtoxinA injections, SMD 1.27 (95% CI
0.51–2.03), 1 Class II study34; confidence in evidence
upgraded due to magnitude of effect
c Ningdong granule (as formulated by Zhao), SMD 0.97
(95% CI 0.45–1.49), 1 Class II study35; confidence in
evidence upgraded due to magnitude of effect (children
only)
c 5-Ling granule, SMD 0.55 (95% CI 0.33–0.76), 1 Class I
study30 (children only)
People with tics and a comorbid diagnosis of ADHD re-
ceiving the following interventions are probably more
likely than those receiving placebo to have reduced tic
severity:
c Clonidine plus methylphenidate, SMD 0.72 (95% CI
0.22–1.22), 1 Class I study31 (children only)
c Methylphenidate, SMD 0.61 (95%CI 0.13–1.10), 1 Class
I study31 (children only)
c Desipramine, SMD 1.13 (95% CI 0.47–1.79), 1 Class II
study36; confidence in evidence upgraded due to magnitude
of effect (children only). Desipramine is now rarely used in
children after several case reports of sudden death associated
with the use of this medication.37
People with tics receiving active DBS of the globus pallidus
are probably more likely than those receiving shamDBS of the
globus pallidus to have reduced tic severity (SMD 0.77 [95%
CI 0.14–1.40], 2 Class II studies38,39 [adults only]).
Low confidence in the evidence
People with tics receiving the following interventions are
possibly more likely than those receiving placebo to have
reduced tic severity:
c Pimozide, SMD 0.66 (95% CI 0.06–1.25), 3 Class II
studies,24,40 confidence in evidence downgraded due to
imprecision
c Ziprasidone, SMD 1.14 (95% CI 0.32–1.97), 1 Class II
study41 (children only)
c Metoclopramide, SMD 1.14 (95% CI 0.33–1.95), 1 Class
II study42 (children only)
c Guanfacine, SMD 0.45 (95% CI 0.03–0.87), 1 Class I
study43 and 2 Class II studies,44,45 confidence in evidence
downgraded due to imprecision (children only)
c Topiramate, SMD 0.91 (95% CI 0.11–1.71), 1 Class II
study46
c Tetrahydrocannabinol, SMD 0.62 (95% CI 0.01–1.22), 1
Class II study47 and 1 Class III study48 (adults only)
For people with tics and a comorbid diagnosis of ADHD,
atomoxetine does not worsen tics relative to placebo (1 Class
II study49) (children only).
Very low confidence in the evidence
There is insufficient evidence to determine whether people
with tics receiving the following interventions are more or less
likely than those receiving placebo to have reduced tic severity:
c Baclofen, SMD 0.55 (95% CI −0.39 to 1.49) 1 Class II
study50; confidence in evidence downgraded due to
imprecision (children only)
c Levetiracetam, SMD 0.22 (95% CI −0.38 to 0.82), 1 Class
II study51; confidence in evidence downgraded due to
imprecision (children only)
c N-acetylcysteine, SMD 0.45 (95% CI −0.27 to 1.17), 1
Class II study52; confidence in evidence downgraded due
to imprecision (children only)
c Omega-3 fatty acids, SMD 0.69 (95% CI 0.00–1.39), 1
Class II study53; confidence in evidence downgraded due
to imprecision (children only)
c Ningdong granule (as formulated by Wang), 1 Class II
study17 (children only)
c Nicotine, SMD 0.38 (95% CI −0.14 to 0.90), 1 Class III
study54 (children only)
c Nicotine patch added to haloperidol, SMD 0.71 (95% CI
0.17–1.25), 1 Class III study55 (children only)
c Mecamylamine, 1 Class II study16 (children only)
c Flutamide, 1 Class I study14 (adults only)
c Riluzole, SMD0.17 (95%CI−0.91 to 1.25), 1Class I study56;
confidence in evidence downgraded due to imprecision
(children only)
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c D-serine, SMD −0.04 (95% CI −1.13 to 1.05), 1 Class I
study56; confidence in evidence downgraded due to
imprecision (children only)
c Ondansetron, SMD 0.53 (95% CI −0.20 to 1.25), 1 Class
III study57
c Pramipexole, SMD 0.00 (95% CI −0.53 to 0.53), 1 Class II
study58; confidence in evidence downgraded due to
imprecision (children only)
c IV immunoglobulin, SMD 0.50 (95% CI −0.24 to 1.24), 1
Class II study59; confidence in evidence downgraded due
to imprecision
c Deprenyl, SMD 0.47 (95% CI −0.05 to 0.99), 1 Class II
study60; confidence in evidence downgraded due to
imprecision (children only)
There is insufficient evidence to determine whether people
with tics receiving the following interventions are more or less
likely than those receiving an alternate intervention to have
reduced tic severity:
c Haloperidol vs pimozide, SMD 0.11 (95% CI −0.41 to
0.62), 2 Class II studies,24,25 confidence in evidence
downgraded due to imprecision
c Risperidone vs pimozide, SMD 0.24 (95% CI −0.51 to
0.99), 2 Class II studies, confidence in evidence down-
graded due to imprecision
c Risperidone vs clonidine, SMD −0.19 (95% CI −1.06 to
0.68), 1 Class II study,e1 confidence in evidence down-
graded due to imprecision (children only)
c Aripiprazole vs risperidone, SMD 0.17 (95% CI −0.34 to
0.68), 1 Class II study,e2 confidence in evidence down-
graded due to imprecision (children only)
c Clonidine vs levetiracetam, SMD 0.86 (95% CI −0.03 to
1.75), 1 Class II studye3 (children only)
c Habit reversal therapy vs exposure and response prevention,
SMD 0.25 (95% CI −0.40 to 0.90), 1 Class II study,e4
confidence in evidence downgraded due to imprecision
c Habit reversal therapy vs educational group treatments,
SMD 0.55 (95% CI −0.17 to 1.27), 1 Class II study,e5
confidence in evidence downgraded due to imprecision
(children only)
c Face-to-face habit reversal therapy vs habit reversal
therapy through video conferencing, SMD 0.24 (95% CI
−0.70 to 1.18), 1 Class II study,e6 confidence in evidence
downgraded due to imprecision (children only)
c Habit reversal therapy by video conferencing vs wait list
control, SMD 0.24 (95% CI −0.65 to 1.14), 1 Class II
study,e7 confidence in evidence downgraded due to
imprecision (children only)
c Relaxation therapy vs minimal therapy, 1 Class III study20
(children only)
c Biofeedback vs sham, 1 Class III study15 (adults only)
c Active DBS of the thalamus vs sham DBS of the thalamus,
SMD 1.58 (95% CI −0.12 to 3.28), 1 Class III studye8
(adults only)
c Active DBS of the centromedian-parafascicular complex vs
sham DBS of the centromedian-parafascicular complex,
SMD 0.99 (95% CI −0.28 to 2.26), 1 Class III studye9
(adults only)
c Continuous theta burst transcranial magnetic stimulation
of the supplementary motor area vs sham transcranial
magnetic stimulation, SMD −0.15 (95% CI −1.29 to 0.99),
1 Class II studye10; confidence in evidence downgraded
due to imprecision
c Repetitive transcranial magnetic stimulation (rTMS) of the
supplementary motor area vs sham stimulation, SMD 0.19
(95% CI −0.69 to 1.07), 1 Class II study,e11 confidence in
evidence downgraded due to imprecision (adults only)
c rTMS of the left motor or prefrontal cortex vs sham
stimulation, 1 Class III study13
In children and adults with TS or a chronic tic
disorder, what are the risks of harm, including
weight gain, elevated prolactin levels,
sedation, drug-induced movement disorders,
hypotension, bradycardia, and ECG changes
with medical treatments compared with
placebo or other active interventions?
Data on harms related to the use of DBS can be found in the
complete and unabridged practice guideline.
Weight gain
People with tics receiving risperidone are probably more likely
to gain weight than people receiving placebo (moderate
confidence, 2 Class II studies27,e1).
People with tics receiving aripiprazole are probably more
likely to gain weight than those receiving placebo (moderate
confidence, 1 Class I study28 and I Class II study29) (children
only).
People with tics receiving aripiprazole are possibly more likely
to have an increase in body mass index and waist circumfer-
ence than people receiving placebo (low confidence, I Class II
study29) (children only).
People with tics and a comorbid diagnosis of ADHD who are
receiving atomoxetine are possibly more likely to have a de-
crease in body weight than people receiving placebo (low
confidence, 1 Class II study49) (children only).
Elevated prolactin levels
People with tics receiving pimozide are possibly more likely to
have increased prolactin levels than people receiving placebo
(low confidence, 1 Class II study24).
People with tics receiving haloperidol are possibly more likely
to have increased prolactin levels than people receiving pla-
cebo (low confidence, 1 Class II study24).
People with tics receiving metoclopramide are possibly
more likely to have greater increases in prolactin levels than
people receiving placebo (low confidence, 1 Class II
study42) (children only).
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Sedation
People with tics receiving risperidone are possibly more likely
to experience fatigue and somnolence than people receiving
placebo (low confidence, 1 Class II study26).
People with tics receiving aripiprazole are possibly more
likely to experience sedation and somnolence than people
receiving placebo (low confidence, 1 Class II study29) (children
only).
People with tics receiving tiapride are probably more likely to
experience higher rates of physical tiredness and sleep dis-
turbances compared with people receiving placebo (moderate
confidence, 1 Class I study30) (children only).
People with tics receiving clonidine are probably more likely
to experience sedation than people receiving placebo (mod-
erate confidence, 1 Class I study31 and 1 Class II study33).
People with tics receiving guanfacine are probably more likely
than those receiving placebo to have drowsiness (moderate
confidence, 1 Class I study43) (children only).
Drug-induced movement disorders
People with tics receiving pimozide are probably more likely
to have extrapyramidal symptoms than people receiving pla-
cebo (moderate confidence, 2 Class II studies40).
People with tics receiving haloperidol are possibly more likely
to have extrapyramidal symptoms than people receiving
pimozide and placebo (low confidence, 1 Class II study24,25).
People with tics receiving risperidone are possibly more likely
to have higher parkinsonism scores on the Extrapyramidal
Symptom Rating Scale Score than people receiving placebo
(low confidence, 1 Class II study26).
People with tics receiving risperidone are possibly more likely
to require antiparkinsonian medication than people receiving
placebo (low confidence, 1 Class II study26).
Blood pressure
People with tics and a comorbid diagnosis of ADHD receiving
desipramine are possibly more likely to have an increase in
diastolic blood pressure than people receiving placebo (low
confidence, 1 Class II study36) (children only).
Heart rate
People with tics and a comorbid diagnosis of ADHD receiving
atomoxetine are possibly more likely to have an increase in
heart rate than people receiving placebo (low confidence, 1
Class II study49) (children only).
People with tics and a comorbid diagnosis of ADHD receiving
desipramine are possibly more likely to have an increased
heart rate than people receiving placebo (low confidence, 1
Class II study36) (children only).
ECG changes
People with tics receiving pimozide are possibly more likely to
have a prolonged QT interval than people receiving placebo
and haloperidol (low confidence, 1 Class II study25).
Discussion
This systematic review summarizes the evidence for efficacy
and harms of interventions for the treatment of tics in indi-
viduals with TS and chronic tic disorders. While there is ev-
idence to support the efficacy of several treatments,
knowledge gaps remain. Many of the interventions have only
been studied in one randomized controlled trial of short du-
ration, with modest sample sizes. The inherent features of tic
disorders, with waxing and waning of symptoms over time,
placebo effects, as well as suppression of tics during clinical
encounters, may confound symptom assessment in clinical
trials. There remains a great need for randomized controlled
trials of interventions for tics to further evaluate both long-
term efficacy and safety. The accompanying practice guideline
makes recommendations based on the findings of this sys-
tematic review, acknowledging the limitations of the currently
available evidence and strongly encouraging psychoeducation
and shared decision-making regarding treatment needs and
priorities.
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